DarioHealth Corp Stock News

DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to earnings of $0.45 per share a year ago.

First quarter revenue of $ 5.8 million reflects an increase of 59% over fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues and reflects a decrease of 18.5% compared to the f

Company to host conference call and webcast at 8:30am ET NEW YORK , May 7, 2024 /PRNewswire/ --  DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announce

Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage diabetes, pre-diabetes, blood pressure, weight and taking a GLP-1 NEW YORK ,

Dario selected to provide integrated and proven solutions to improve employee cardiometabolic health NEW YORK , April 18, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company

Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens NEW YORK , April 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or t

Dario selected to provide integrated approach to improve employee cardiometabolic health - including support for those taking a GLP-1 medication - musculoskeletal and behavioral health NEW YORK , Apri

DarioHealth Corp. (DRIO) Q4 2023 Earnings Call Transcript

Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2B2C revenue increased. 2023 B2B2C,

Company to host conference call and webcast at 8:30am ET NEW YORK , March 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announce

Study presented at ATTD 2024 is the first of a planned series examining the impact of Dario's integrated cardiometabolic solution as a means to address weight and diabetes with or without a GLP-1 Addi

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that management will participate in the Cowen 44th Annual Health

NEW YORK , Feb. 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that management will participate in the Cowen 44th Annual Healt

Expecting nearly doubling Dario's pro forma revenues in 2023 Acquisition is immediately accretive to revenue and gross margins and expected to accelerate path to profitability Concurrent with the acqu

Dario's integrated solution to support improved whole health gains traction in public and labor market NEW YORK , Jan. 11, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Compa